All In Biotech

Drug Trial Radar · NCT06798909

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

Kidney Transplant Preemptive Therapy or Prophylaxis (KPoP) for CMV Prevention in D+R- Recipients

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jul 22, 2025

Primary completion

Nov 30, 2030

Study completion May 31, 2031

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \[both dose adjusted per Food and Drug Administration (FDA) label\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study. Estimated Time to Complete Enrollment: 4 years

Conditions

  • Cytomegalovirus (CMV)
  • Kidney Transplant; Complications
  • Kidney Diseases

Interventions

  • Valganciclovir (Pre-emptive CMV Therapy)Drug

    Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.

  • Valganciclovir CMV ProphylaxisDrug

    Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of endpoint committee (EC)-confirmed CMV disease (either syndrome or end-organ) by 1-year post-transplant.Time frame: Within 1-year post-transplant

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco School of Medicine

    San Francisco, California · Recruiting

  • University of Miami Miller School of Medicine

    Miami, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Not yet recruiting

  • Robert Wood Johnson Health Network Barnabas Health

    Livingston, New Jersey · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Not yet recruiting

  • Medical College of Virginia Commonwealth

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.